araag2/HINT huggingface dataset:
Clinical trial NCT00513968 (phase 1, status: completed)
Conditions: chronic hepatitis b
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: adefovir
SMILES: CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis B infected patient documented with positive HBsAg for 3 months and
             more at screening

          -  Chronic hepatitis B infected patient with positive HBeAg at screening

          -  Patient who has not treated with interferon alpha, lamivudine or adefovir within 3
             months before study entry

          -  HBV DNA more than 1x10^5 copies/mL through COBAS Amplicor HBV monitor assay or bDNA
             method at screening

          -  Patient with HBV DNA decrease more than 10-fold compared to the baseline after 8 weeks
             treatment with adefovir

          -  Patient with ALT value between ULN x 1.5 and ULN x 5 at screening

          -  Patient given a written consent voluntarily

        Exclusion Criteria:

          -  Have uncompensated liver disease

          -  Serum creatinine > ULN x 1.5

          -  Are positive for Hepatitis C, hepatitis D or HIV infection (confirmed by ELISA assay)

          -  Had a previous liver or bone marrow transplant

          -  Are currently taking any immunosuppressant or any possible immune modulatory drugs

          -  Women who are pregnant or breastfeeding

          -  Woman or man who plans a birth for study duration

          -  Any experience of severe adverse drug reaction or any medical history of severe
             allergic disease

          -  Patient with any severe disease (for example, heart failure, renal failure,
             pancreatitis, diabetes mellitus) affecting the study in discretion of investigator
             except liver disease

          -  Patient with any other liver disease but hepatitis B (for example, hemochromatosis,
             Wilson's disease, alcoholic/non-alcoholic liver diseae)

          -  Patient with intrahepatic tumors confirmed by imaging (liver biopsy)and abnormally
             increased alpha-fetoprotein

          -  Patient with any present malignant tumor except liver or its history

          -  Other inappropriate patient in discretion of investigator
Clinical trial NCT00346879 (phase 1, status: withdrawn)
Conditions: morbid obesity
ICD codes: E66.2, E66.01
Drugs: fondaparinux
SMILES: CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
Reason stopped: 
    funding withdrawn; study closed due to lack of accrual.
  
Eligibility criteria:

        Inclusion Criteria:

        - Age 19-65 BMI: 35-65 Negative pregnancy test on day of study

        Exclusion Criteria:

        - Blood Pressure < or = to 160/90 Temperature > 37.5 C (99.5 F) Nursing a baby Positive
        pregnancy test on day of study. Medications: History of regular treatment with
        anticoagulants or any anti-platelet agents including aspirin and other NSAIDS; use of
        aspirin or other NSAIDS within 1 month of study.

        Past Medical History:

        Cerebrovascular accident (including transient ischemic attacks) within 6 months of study.

        Diabetic retinopathy as documented by positive fundoscopy in previous 3 months. Active
        peptic ulcer disease, by EGD or Ba meal, within 3 months of study. Known bleeding disorder.
        Known thrombophilia History of heparin induced thrombocytopenia. History of bacterial
        endocarditis. Known hypersensitivity to fondaparinux. Ulcerative colitis. History of GI
        bleeding History of hematuria Recent surgery (in previous 3 months). Recent trauma - road
        traffic accident (previous 3 months).

        Laboratory Values:

        Platelet count < or = to 100,000. Hemoglobin <12g/dl - women or <14g/dl - men. Prothrombin
        time > 13s Activated partial thromboplastin time (APTT) > 35s Liver function test
        parameters: ALT > 60u/L, AST > 40u/L, γ-GT >85u/L, Alkaline phosphatase >251 u/L or total
        bilirubin > 1.3 mg/dl.

        Estimated urinary creatinine clearance < 50 mls/min. Hematuria on urine dipstick.
Clinical trial NCT00003194 (phase 1, status: terminated)
Conditions: unspecified childhood solid tumor, protocol specific
ICD codes: H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: carboplatin, cyclophosphamide, etoposide, thiotepa, topotecan hydrochloride
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Reason stopped: 
    study enrollment did not meet expected goals
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven recurrent or refractory pediatric solid tumor

          -  Bone marrow metastases allowed

        PATIENT CHARACTERISTICS:

        Age:

          -  1 to 30

        Performance status:

          -  0-2

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  Absolute neutrophil count at least 1,000/mm3

          -  Platelet count at least 100,000/mm3 (transfusion independent)

          -  Hemoglobin at least 10 g/dL (RBC transfusion allowed)

        Hepatic:

          -  Bilirubin no greater than 1.5 times normal

          -  SGOT no greater than 2.5 times normal

        Renal:

          -  Adequate renal function as defined by one of the following:

               -  GFR by creatinine clearance

               -  Radioisotope GFR

               -  Iothalamate at least 70 mL/min

        Cardiovascular:

          -  Adequate cardiac function as defined by one of the following:

               -  Ejection fraction at least 55% by MUGA

               -  Fractional shortening at least 28% by echocardiogram

        Neurologic:

          -  Adequate CNS function as defined by:

               -  Seizure disorder, if present, controlled by anticonvulsants

               -  CNS toxicity no greater than grade 2

        Other:

          -  No uncontrolled infections

          -  Not pregnant or nursing

          -  No allergy to platinum compounds

          -  No history of allergy to etoposide (unless mobilization phase not required)

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Recovered from prior immunotherapy

          -  At least 1 week since prior cytokines

          -  At least 3 months since prior bone marrow or peripheral blood stem cell
             transplantation

          -  No concurrent immunomodulator

          -  No concurrent cytokines

        Chemotherapy:

          -  At least 3 weeks (6 for nitrosourea) since prior chemotherapy and recovered

          -  No prior thiotepa

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Recovered from prior radiotherapy

          -  At least 6 months since prior total body irradiation conditioning

          -  No concurrent radiotherapy to greater than 10% of total liver, lung, or bone marrow

        Surgery:

          -  Not specified
Clinical trial NCT00492869 (phase 1/phase 2, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: aeb071
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12
Eligibility criteria:

        Inclusion:

          -  Male and female patients of any race 18 years or older

          -  Adult recipients of kidney transplant from a deceased or living donor

          -  Recipients of a functioning kidney within 24 hours post transplant

        Exclusion:

          -  Need for medication prohibited by the protocol

          -  Patients or donors infected with Hepatitis B,C or HIV

          -  Patients with a history of cancer within last 5 years

          -  Patients with history of significant cardiac disorder

          -  Patients of high-risk immunological status

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00303576 (phase 1/phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: dapivirine (tmc120) vaginal gel
SMILES: CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-negative

          -  Willing to participate and sign an informed consent

          -  Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to
             a study group that includes the possibility of being assigned to a placebo group.

          -  Willing to use two forms of contraception during the study.

          -  Willing to undergo pelvic examinations with colposcopy and photographic documentation
             according to the protocol throughout the study.

          -  Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of
             36 days between menses.

          -  Willing to abstain from using any vaginal product (other than the study product or
             placebo).

          -  Willing to be sexually abstinent from randomization until completion of Day 7
             evaluations.

        Exclusion Criteria:

          -  Currently pregnant or breast-feeding.

          -  Clinically detectable genital abnormality on the vulva, vaginal walls or cervix.

          -  Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal
             candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions.

          -  Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization.

          -  Symptomatic bacterial vaginosis and unwilling to undergo treatment.

          -  Women who require treatment for tuberculosis (TB) within 21 days prior to
             randomization.
Clinical trial NCT00118456 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: aee788
SMILES: [H][C@](C)(N=C1N=CNC2=C1C=C(N2)C1=CC=C(CN2CCN(CC)CC2)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed solid tumor

          -  Adequate hematologic, renal and hepatic function

          -  Age ≥ 18 years

          -  Karnofsky performance status score ≥ 70%

          -  Life expectancy ≥ 12 weeks

        Exclusion Criteria:

          -  Active brain metastases

          -  Peripheral neuropathy > grade 2

          -  Diarrhea > grade 1

          -  Gastrointestinal (GI) dysfunction

          -  Compromised cardiac function

          -  Concurrent severe and/or uncontrolled medical conditions
Clinical trial NCT00046839 (phase 1/phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: celecoxib
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer

               -  Inoperable stage IIB OR

               -  Unresectable stage IIIA or IIIB

               -  No evidence of hematogenous metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 2 AND more than 5% weight loss over the past 3 months OR

          -  Zubrod 0-1 AND less than 5% weight loss over the past 3 months and refuses
             chemotherapy or are medically unable to tolerate combined modality therapy

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin no greater than 2 times upper limit of normal

          -  International Normalized Ratio (INR) no greater than 3.0 if taking warfarin

        Renal

          -  Creatinine clearance at least 50 mL/min

        Other

          -  No active gastrointestinal ulcers or bleeding within the past 3 months

          -  No other malignancy within the past 3 years except nonmelanoma skin cancer

          -  No known hypersensitivity to celecoxib

          -  No prior allergic-type reactions to sulfonamides

          -  No prior asthma, urticaria, or allergic-type reactions to aspirin or other
             nonsteroidal anti-inflammatory drugs (NSAIDs)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior neoadjuvant chemotherapy

          -  No concurrent chemotherapy

        Endocrine therapy

          -  No concurrent corticosteroids

        Radiotherapy

          -  No prior thoracic radiotherapy

        Surgery

          -  No prior complete or subtotal tumor resection

        Other

          -  No concurrent NSAIDs, lithium, furosemide, or angiotensin-converting enzyme inhibitors

          -  Concurrent aspirin (325 mg/day) for cardioprotection allowed
Clinical trial NCT00528619 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: sunitinib, pemetrexed, cisplatin, carboplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of a solid cancer which is not responsive to standard
             therapy or for which no standard therapy exists.

          -  Patient has a good performance status (ECOG 0 or 1).

        Exclusion Criteria:

          -  Prior treatment with either pemetrexed or SU011248.

          -  Coughing up blood within 4 weeks before starting study treatment (small amounts okay).

          -  Hypertension that cannot be controlled by medications.
Clinical trial NCT01291004 (phase 1, status: completed)
Conditions: follicle development, ovarian follicle, follicle count, follicle size, oral contraceptive
ICD codes: T38.4X1A, T38.4X1D, T38.4X1S, T38.4X2A, T38.4X2D, T38.4X2S, T38.4X3A
Drugs: desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal, non-pregnant, non-lactating women age 18-35 years old

          -  Body Mass Index (BMI) ≥18 kg/m² and <30 kg/m²

          -  Regular spontaneous menstrual cycle

          -  Others as dictated by Food and Drug Administration (FDA)-approved protocol

        Exclusion Criteria:

          -  Any condition which contraindicates the use of combination oral contraceptives

          -  Known thrombophlebitis or thromboembolic disorders; known or suspected clotting
             disorders; thrombogenic valvulopathies or rhythm disorders

          -  Migraine headaches with focal, neurological symptoms

          -  Others as dictated by FDA-approved protocol
Clinical trial NCT00669942 (phase 1/phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients with active rheumatoid arthritis in combination with a stable
             dose of methotrexate aged 18-75 years may participate in this trial.

          -  Post menopausal or surgically sterile female patients are allowed. Women of
             child-bearing potential may participate if they are on a stable dose of methotrexate
             and if they are practicing effective contraception for at least 6 months prior to
             screening, willing to use 2 forms of contraception, including at least 1 barrier
             method during the study and for at least 2 months following the
             completion/discontinuation of the study.

          -  Patients must have a diagnosis of active rheumatoid arthritis of stages I, II or III
             (ACR 1987 revised classification for criteria for RA). Disease duration of at least 6
             months prior to randomization is essential;

        Exclusion Criteria:

          -  Current treatment with anti-TNF-α or anti IL-1 therapy (or other biological therapy).

          -  Patients with congestive heart failure or poorly controlled diabetes mellitus (HbA1c
             value ≥10%).

          -  Presence of any major chronic inflammatory autoimmune diseases like psoriasis,
             psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease or SLE that can
             mimic rheumatoid arthritis diagnosis or that can interfere with efficacy evaluation in
             the study.

          -  History of renal trauma, glomerulonephritis or patient with one kidney.

          -  Pregnant or breastfeeding women will be excluded.

          -  A positive tuberculin skin test.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00834899 (phase 1/phase 2, status: terminated)
Conditions: sickle cell disease
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: eptifibatide, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow accrual and no cost extension not approved by nhlbi
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age between 18 and 55 years

          2. Have confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia

          3. Have a serum creatinine </= 1.2 mg/dl

          4. Have serum transaminase values < 3 times upper limits of normal

          5. Have a platelet count >/= 150 x 10^9/L

          6. Have normal baseline coagulation profile

          7. Sudden onset of pain involving one or more sites and typical of usual pain episodes

          8. Have adequate intravenous access

          9. Be able to understand the requirements of the study and be willing to give informed
             consent

         10. Women of child-bearing age must be practicing (and will continue to practice for the
             course of the study) an adequate method of contraception (oral contraception,
             depo-provera, bilateral tubal ligation or barrier method)

        Exclusion Criteria:

          1. Have a baseline hemoglobin < 6.0 gm/dl

          2. Have a history of major gastrointestinal bleeding or a bleeding diathesis

          3. Have an ongoing episode of acute chest syndrome

          4. Have a past history of clinically overt stroke(s)

          5. Have severe hypertension (systolic blood pressure > 200mmHg and/or diastolic BP
             >110mmHg) not adequately controlled on hypertensive medication

          6. Have had major surgery within the six weeks preceding enrollment

          7. Are pregnant or breastfeeding

          8. Are on chronic anticoagulation or antiplatelet (including non-steroidal
             anti-inflammatory drugs) therapy

          9. Have a history of metastatic cancer

         10. Are on a chronic transfusion program or have received a blood transfusion in the prior
             8 weeks

         11. Have a positive urine toxicology screen for phencyclidine, cocaine or amphetamines.

         12. Have a history of alcohol abuse

         13. Have received any investigational drugs within the past 4 weeks.
Clinical trial NCT00609739 (phase 1/phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, cis-retinoic acid
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients age 0-18 with juvenile myelomonocytic leukemia (JMML) who have relapsed or
             have residual disease after allogeneic HCT. Residual disease is defined as failure to
             eradicate original disease without prior documentation of remission. Relapse is
             defined as reappearance of i) leukocytosis with absolute monocytosis >1 x 10^8/L, ii)
             presence of immature myeloid cells in the peripheral circulation in two consecutive
             bone marrow specimens taken at least one month apart, or iii) presence of clonal
             cytogenetic abnormality. The diagnosis of relapse will be supported by the return of
             an abnormal cytogenetic marker (if present at diagnosis) or the presence of host cells
             by RFLP or other method.

          -  Patients should be at least 6 months from first hematopoietic cell transplant (HCT) if
             clinically stable. (If JMML is rapidly progressive, second HCT may be performed
             earlier).

               -  Adequate major organ function including:

                    -  Cardiac: ejection fraction ≥45%

                    -  Pulmonary: FEV >50%, DLCO >50%

               -  Renal: creatinine clearance ≥40 mL/min

                    -  Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy,
                       ascites)

               -  Karnofsky performance status ≥70% or Lansky score ≥50%

          -  Written informed consent.

        Exclusion Criteria:

          -  Active uncontrolled infection within one week of HCT.
Clinical trial NCT02012777 (phase 1, status: terminated)
Conditions: sickle cell disease
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: propranolol
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    inability to recruit patients into the study.
  
Eligibility criteria:

        Inclusion Criteria:

          1. diagnosis of HbSS or HbSBeta0Thal

          2. age 10-17 years

          3. Weight 30kg or greater

          4. Hb 7mg/dL or greater

          5. informed consent

        Exclusion Criteria:

          1. History of vaso-occlusive crisis during the past 6 weeks, or history of transfusion
             during the past 3 months.

          2. pregnancy

          3. history of heart failure, myocardial infarction, asthma, bradyarrythmias, hypotension,
             thyroid disease, diabetes, renal insufficiency

          4. concurrent medications: any antihypertensive medication, diuretics, thyroid
             replacement medications, any arrythmia medication, insulin, hypoglycaemic medication

          5. history of allergy to sulfonamides

          6. elevated BUN or creatinine